Effect of a Black Garlic Extract on Cholesterol LDL Levels (ESACTIVO)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04010565 |
Recruitment Status :
Completed
First Posted : July 8, 2019
Last Update Posted : February 28, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
One of the most characteristic components of the Mediterranean diet is garlic (Allium sativum L.), food to which has been attributed protective properties against cardiovascular diseases (CVD). Recently, several methods of garlic processing have been developed to obtain derivatives with milder organoleptic characteristics and a longer shelf life than habitual garlic derivates. One of these strategies is the aging of the garlic by high temperatures treatment that eliminates the taste and characteristic odor of garlic and gives it a dark color, a sweet taste and a slimy texture. Because the changes in the visual and organoleptic characteristics, the garlic obtained by aging at high temperatures is named black garlic.
Interestingly, these modifications translate into an increase in their antioxidant power and their protective capacity against the development of CVDs, mainly due to the formation of melanoidins and to the content of organosulfur derivatives of cysteine compounds, such as S-allyl-cysteine (SAC) and alliin.
Hypothesis of the study: The daily administration of a new extract of aged black garlic (SANE), with a higher concentration of bioactive compounds and lower unwanted compounds will lower cholesterol levels of low density lipoproteins (LDL-c), and will produce favorable changes on other markers of cardiovascular risk in individuals with moderate hypercholesterolemia.
Each 250 mg of SANE contains 0.5% in SAC, which will mean an amount of 1.25 mg of SAC per day, about 5 times more than SAC levels present in many of the black garlic products marketed.
The main objective was to evaluate the effect of the daily intake of a SANE with a higher concentration of bioactive compounds, SAC and alliin, and minor unwanted compounds such as simple sugars and furfural derivatives, in combination with dietary recommendations, on LDL-c levels in individuals with moderate hypercholesterolemia.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cardiovascular Diseases | Dietary Supplement: Aged black garlic extract Dietary Supplement: Placebo | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 67 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Masking Description: | The consumption of SANE and placebo will be in the form of tablets with the same appearance, of 550 mg / tablet, guaranteeing that the study is blind both for the researchers of the project and for the participants (double blind). |
Primary Purpose: | Prevention |
Official Title: | Effect of a Black Garlic Extract With Greater Concentration of Bioactive Compounds and Lower Content in Undesired Compounds on Cholesterol LDL Levels. Chronic, Randomized, Crossover, Controled and Double Blind Study |
Actual Study Start Date : | July 24, 2019 |
Actual Primary Completion Date : | December 19, 2019 |
Actual Study Completion Date : | December 19, 2019 |
Arm | Intervention/treatment |
---|---|
Experimental: Extract of aged black garlic
Participants will consume a tablet of 550 mg daily with 250 mg of aged black garlic extract and 300 mg of excipients (microcrystaline cellulose 90 mg; dicalcium phosphate 157 mg; crosscamellose sodium 10 mg; magnesium stearate 7 mg; sodium alignate 3.06 mg; stearic acid 0.03 mg; oleic acid 1.54 mg; medium chain triglycerides 2.80 mg; ethylcellulose 13.17 mg; hydroxypropylcellulose 4.86 mg; hydroxypropylmethylcellulose 4.86 mg; talcum 2.88 mg; titanium dioxide 1.80 mg; vanilla aroma 1.00 mg) .
|
Dietary Supplement: Aged black garlic extract
Participants will intake a tablet with 250 mg of a aged black garlic extract with higher concentration of bioactive compounds S-allyl cysteine and alliin, and minor unwanted compounds such as simple sugars and furfural derivatives. In addition, during the course of the study, participants will be urged to follow dietary guidelines according to a heart-healthy diet established by nutritionists and that they will adhere to European guidelines for the treatment of dyslipidemias. |
Placebo Comparator: Placebo
Participants will consume a tablet of 550 mg daily with 550 mg of excipients (microcrystaline cellulose 342.5 mg; dicalcium phosphate 154.5 mg; crosscamellose sodium 10 mg; magnesium stearate 7 mg; sodium alignate 3.06 mg; stearic acid 0.03 mg; oleic acid 1.54 mg; medium chain triglycerides 2.80 mg; ethylcellulose 13.17 mg; hydroxypropylcellulose 4.86 mg; hydroxypropylmethylcellulose 4.86 mg; talcum 2.88 mg; titanium dioxide 1.80 mg; vanilla aroma 1.00 mg).
|
Dietary Supplement: Placebo
Participants will intake a tablet with 250 mg of microcrystalline cellulose. In addition, during the course of the study, participants will be urged to follow dietary guidelines according to a heart-healthy diet established by nutritionists and that they will adhere to European guidelines for the treatment of dyslipidemias. |
- LDL-c levels [ Time Frame: At week 1, week 3 and week 6 for each of the two treatments (SANE and placebo). ]Serum LDL-c levels will be measured by standardized methods in Cobas Mira Plus autoanalyzer (Roche Diagnostics Systems, Madrid, Spain).
- Measures of body weight [ Time Frame: At week 1, week 3 and week 6 for each of the two treatments (SANE and placebo). ]Body weight measured by TANITA SC330.
- Measures of height [ Time Frame: At week 1, week 3 and week 6 for each of the two treatments (SANE and placebo). ]Height measured by standardized methods.
- Measures of BMI [ Time Frame: At week 1 for each of the two treatments (SANE and placebo). ]Weight and height will be combined to report BMI in kg/m^2.
- Measures of waist circumference [ Time Frame: At week 1, week 3 and week 6 for each of the two treatments (SANE and placebo). ]Waist circumference using a measuring tape.
- Bood pressure (measured in mmHg) [ Time Frame: At week 1, week 3 and week 6 for each of the two treatments (SANE and placebo). ]Systolic and diastolic blood pressure will be measured twice after 2-5 minutes of patient respite, seated, with one-minute interval in between, using an automatic sphygmomanometer (OMRON HEM-907; Peroxfarma, Barcelona, Spain).
- Lipid metabolism [ Time Frame: At week 1, week 3 and week 6 for each of the two treatments (SANE and placebo). ]Total cholesterol, HDL-c, TG, NEFAs, Apo B and Apo A1 plasma levels will be measured by standardized methods in Cobas Mira Plus autoanalyzer (Roche Diagnostics Systems, Madrid, Spain). oxLDL, PLTP plasma levels will be measured by human ELISA kits.
- Glucose metabolism [ Time Frame: At week 1, week 3 and week 6 for each of the two treatments (SANE and placebo). ]Glucose and insulin plasma levels will be measured by standardized methods in Cobas Mira Plus autoanalyzer (Roche Diagnostics Systems, Madrid, Spain).
- Inflammation [ Time Frame: At week 1, week 3 and week 6 for each of the two treatments (SANE and placebo). ]IL-6 plasma levels will be measured by standardized methods in Cobas Mira Plus autoanalyzer (Roche Diagnostics Systems, Madrid, Spain). MCP-1 and TNF alpha will be measured by human ELISA kits.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Men and women over 18 years of age.
- Fasting serum LDL-c concentration ≥ 115 mg/dL.
- Sign the informed consent.
Exclusion Criteria:
- BMI ≥ 35 kg/m^2
- LDL-c serum levels <115 mg/dL
- Serum glucose levels higher than 126 mg/dL
- Take supplements or multivitamin supplements or phytotherapeutic products that interfere with the treatment under study up to 30 days before the start of the study.
- Be a smoker
- Follow a hypocaloric diet and/or pharmacological treatment for weight loss.
- Anti-hypertensive treatment.
- Presenting anemia (hemoglobin ≤ 13 g/dL in men and ≤ 12 g/dL in women).
- Present some chronic gastrointestinal disease.
- Present some chronic disease in clinical manifestation.
- Being pregnant or intending to become pregnant.
- Be in breastfeeding period.
- Participate in or have participated in a clinical trial or nutritional intervention study in the last 30 days prior to inclusion in the study.
- Being unable to follow the study guidelines.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04010565
Spain | |
Centro Tecnológico de Nutrición y Salud (Eurecat-Reus) | |
Reus, Tarragona, Spain, 43203 |
Principal Investigator: | Rosa Solà, Dr | Centro Tecnológico de Nutrición y Salud (Eurecat_Reus). Reus, Tarragona, Spain. |
Responsible Party: | Technological Centre of Nutrition and Health, Spain |
ClinicalTrials.gov Identifier: | NCT04010565 |
Other Study ID Numbers: |
ESACTIVO |
First Posted: | July 8, 2019 Key Record Dates |
Last Update Posted: | February 28, 2022 |
Last Verified: | February 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Cholesterol LDL Black garlic extract S-allyl cysteine |
Cardiovascular Diseases |